1. Home
  2. AKBA vs FPH Comparison

AKBA vs FPH Comparison

Compare AKBA & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.88

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Logo Five Point Holdings LLC

FPH

Five Point Holdings LLC

HOLD

Current Price

$5.13

Market Cap

383.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
FPH
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
343.4M
383.2M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
AKBA
FPH
Price
$0.88
$5.13
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.67
N/A
AVG Volume (30 Days)
3.9M
182.4K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
$110,020,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.40
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$4.60
52 Week High
$3.32
$6.64

Technical Indicators

Market Signals
Indicator
AKBA
FPH
Relative Strength Index (RSI) 29.90 45.88
Support Level $0.85 $4.91
Resistance Level $1.54 $5.16
Average True Range (ATR) 0.07 0.15
MACD -0.05 -0.01
Stochastic Oscillator 7.30 6.82

Price Performance

Historical Comparison
AKBA
FPH

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: